GH — Guardant Health, Inc.
GH dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Jul 2026)
- Float: 127.0M shares
Dilution filings
- S-3ASR
- S-3ASR
$170.73-4.51%
Last close: · regular session
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Jul 2026). Float: 127.0M shares. Latest SEC filing: 8-K on Jul 30, 2026. GH closed at $170.73 (-4.51%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GH in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 1,999
- Website: https://guardanthealth.com
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Latest SEC filings for GH
Latest GH news
- Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Read article
- Guardant Health loses challenge regarding DNA sequencing patent Read article
- Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 Read article
- Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 Read article
- Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.